Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin for Social Cognition in Autism-Spectrum Disorder
DRKS00010053Phase 2Recruiting
- Sponsor
- Max Planck Institute for Human Cognitive and Brain Sciences
- Start
- Apr 2016
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of oxytocin in Autism Spectrum Disorder (ASD), Asperger syndrome and atypical autism (PDD-NOS) (2 arms), sponsored by Max Planck Institute for Human Cognitive and Brain Sciences. Primary endpoint: Modulation of social cognition after intranasal oxytocin. Started Apr 2016; status: recruiting.
02
Drugs
oxytocin
03
Conditions
Autism Spectrum Disorder (ASD)Asperger syndromeatypical autism (PDD-NOS)
Beyond the preview
Go deeper on DRKS00010053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00010053.